Regulation & market

503B outsourcing facility

A compounding facility registered with FDA that may produce larger batches without patient-specific prescriptions, and must follow GMP.

In plain terms

The 503B category was created after a 2012 fungal meningitis outbreak traced to a compounding pharmacy operating at manufacturing scale under pharmacy rules. 503B facilities register with FDA, are subject to inspection, and must comply with GMP.

Guides that use this term

Are peptides legal? What the FDA actually says

BPC-157, TB-500, CJC-1295 and ipamorelin: what the FDA has actually published about each, why “removed from Category 2” does not mean cleared, and what is still unlawful to compound.

Compounded semaglutide and tirzepatide: what changed

The shortages ended, and with them the enforcement discretion that allowed mass compounding of semaglutide and tirzepatide. What FDA actually said, with the dates, and what remains permitted.

Sources

FDA — Compounding and the FDA: Questions and Answers

Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.